Buprenorphine Prescriber Supply in 2026: Who Can Prescribe and What Gates Your Growth

Buprenorphine prescribing got structurally easier in recent years and most operators have not updated their hiring assumptions to match. The constraint on a virtual opioid use disorder program in 2026 is rarely who is legally allowed to prescribe. It is state licensure, and it is a federal deadline sitting at the end of the year.

Who can prescribe buprenorphine now?

The separate waiver that used to be required was eliminated by the Consolidated Appropriations Act of 2023. Any practitioner holding a DEA registration with Schedule III authority may prescribe buprenorphine for opioid use disorder, subject to a one-time training requirement introduced by the MATE Act.

Practically, that means physicians, nurse practitioners and physician assistants with the appropriate DEA registration and state prescriptive authority. The old patient caps are gone.

The eligibility question is therefore mostly settled. If your hiring plan still assumes a scarce pool of waivered prescribers, it is working from a pre-2023 map.

So what actually gates growth?

Three things, in order.

State licensure. A prescriber can only treat patients in states where they hold a license. For a program expanding state by state this is the binding constraint, exactly as it is for the rest of virtual care.

State-level rules on top of federal. Some states impose their own requirements on buprenorphine prescribing, prescription monitoring checks, or telehealth encounters for controlled substances. Federal permission does not override a state restriction.

The December 31, 2026 federal deadline. The telemedicine flexibilities that allow controlled substance prescribing without a prior in-person exam expire at the end of this year, and the permanent replacement has not been finalized. We covered the detail in the DEA prescribing deadline breakdown.

DEA has separately expanded buprenorphine treatment via telemedicine, which is a distinct rule from the general flexibility extension. Worth confirming which one your model relies on, because they have different timelines.

Who else the program needs

Prescribers are the piece operators over-index on. A functioning opioid use disorder program also needs counselors, care coordination, and peer recovery support, and those roles are far deeper in supply and far easier to license across states.

If prescriber capacity is your bottleneck, the answer is usually to reduce how much of the care model depends on prescriber time rather than to hire more prescribers. Induction and stabilization need them. Much of ongoing support does not.

What to do before year end

Map which of your patients have never had an in-person evaluation with their prescriber, since that is the population the federal deadline attaches to.

Confirm state controlled substance registrations separately from medical licenses. They are distinct and they lapse independently.

Build the counselor and peer support side of the team now, so that if prescriber capacity tightens, the program degrades rather than stops.

Frequently asked questions

Who can prescribe buprenorphine for opioid use disorder?Any practitioner holding a DEA registration with Schedule III authority, subject to a one-time training requirement under the MATE Act. The separate waiver requirement was eliminated by the Consolidated Appropriations Act of 2023, and the former patient caps no longer apply. In practice that means physicians, nurse practitioners and physician assistants with appropriate DEA registration and state prescriptive authority.

Is finding waivered prescribers still the constraint?No. That constraint largely ended in 2023. A hiring plan built around a scarce pool of waivered prescribers is working from an outdated map. The current constraints are state licensure, state-level prescribing rules, and the federal telemedicine deadline.

What is the December 31, 2026 deadline?The telemedicine flexibilities allowing controlled substance prescribing without a prior in-person examination expire at the end of 2026. The permanent replacement framework has not been finalized. This applies to patients who have never been examined in person by the prescriber.

Does federal permission override state rules?No. Some states impose their own requirements on buprenorphine prescribing, prescription monitoring checks, or telehealth encounters involving controlled substances. Federal authorization does not remove a state restriction.

What roles besides prescribers does an OUD program need?Counselors, care coordination and peer recovery support. These roles have far deeper supply and are easier to license across states. If prescriber capacity is the bottleneck, reducing how much of the care model depends on prescriber time usually works better than hiring more prescribers.

DirectShifts sources and licenses prescribers and behavioral health clinicians across states for virtual care operators. Tell us which states you are trying to reach.